For condition: Hidradenitis Suppurativa
The Hidradenitis Suppurativa (HS) Clinical Research Study (30 Weeks)
Study Summary
Who Can Participate?
Adults ages 18+ with moderate to severe hidradenitis suppurativa (HS) may be eligible to participate.
Inclusion Criteria
- Has experienced HS symptoms for at least 6 months
- Have HS lesions present in least 2 distinct body areas
- Have HS defined as a total of >5 inflammatory lesions (i.e, number of abscesses plus number of inflammatory nodules)
- Have either had an inadequate response, intolerance, recurrence, or had a contraindication to oral antibiotics for treatment of HS
Participant Information
- Participate and receive study treatment at no cost
- Regular visits with study doctors who specialise in treating HS (12 visits)
- Will receive either an investigative injection treatment (study drug) or a placebo
- Reimbursement for study-related expenses may be provided
How Long Will The Study Last?
- Participants will be asked to visit the study centre about 12 times over a period of about 30 weeks
Note: This study is sponsored by Sanofi-Aventis Canada Inc.
For more information about this trial, please visit ClinicalTrials.gov
